ImmunityBio Stock Jumps As New Bladder Cancer Guideline Boosts Anktiva Use - ImmunityBio (NASDAQ:IBRX)
Published on March 17, 2026.
ImmatheniaBio (NASDAQ:IBRX) shares rose 2.01% as a new Bladder Cancer Guideline expanded the use of Anktiva in combination with Bacillus Calmette-Guérin (BCG) for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with papillary-only disease. The update expands previous NCCN clinical guideline recommendations, which included patients with carcinoma in situ (CIS) with or without papillary disease. Anktiv received FDA approval in April 2024 for its use in conjunction with BCG and is currently covered by insurance plans representing over 100 million insured patients in the US. The company is also working with payers and healthcare institutions to support education and appropriate access consistent with approved labeling.
Related Articles
New Space ETF Promises Weekly Income As Industry Boom Takes Off - Tuttle Capital Space Industry Income Blast ETF (BATS:SPCI)
The Tuttle Capital Space Industry Income Blast ETF (SPCI) aims to generate weekly income through dual options-based strategies, blending existing exposure to space industries.
Longeveron Braces For Q4 Results Following Recent Funding Boost - Longeveron (NASDAQ:LGVN)
Longeveron shares rose 9.01% following a $30 million fundraising boost, with analysts expecting a 38-cent loss for Q4.
These high-yielding energy plays could be a ‘win/win,’ regardless of what happens with oil, Bank of America says
Bank of America suggests investing in high-yielding energy plays like MLPs and Energy Transfer to diversify amid volatile oil prices and regulatory concerns.